Page 52 - 2019_10 resto del Mondo_web

P. Valent et al.
proliferative neoplasms. Nat Rev Cancer.
2017;17(7):425-440.
77. Mainwaring CJ, Shutt J, James CM. Not all
cases of idiopathic thrombocytopenic pur- pura (correction of pupura) are what they might first seem. Clin Lab Haematol. 2002;24(4):261-262.
78. Cai Y, Teng R, Lin Z, Zhang Y, Liu H. Chronic myelomonocytic leukemia present- ing as relapsing thrombotic thrombocy- topenic purpura. Aging Clin Exp Res. 2013;25(3):349-350.
79. Hadjadj J, Michel M, Chauveheid MP, Godeau B, Papo T, Sacre K. Immune throm- bocytopenia in chronic myelomonocytic leukemia. Eur J Haematol. 2014;93(6):521- 526.
80. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syn- dromes: consensus statements and report from a working conference. Leuk Res. 2007;31(6):727-736.
81. Mufti GJ, Bennett JM, Goasguen J, et al. Diagnosis and classification of myelodys- plastic syndrome: International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) consensus pro- posals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008;93(11):1712-1717.
82. Germing U, Strupp C, Giagounidis A, et al. Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. Leuk Res. 2012;36(6):727-734.
83. Della Porta MG, Travaglino E, Boveri E, et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia. 2015;29(1):66-75.
84. Goasguen JE, Bennett JM, Bain BJ, Vallespi T, Brunning R, Mufti GJ; International Working Group on Morphology of Myelodysplastic Syndrome. Morphological evaluation of monocytes and their precursors. Haematologica. 2009;94(7):994-997.
85. Sperr WR, Escribano L, Jordan JH, et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of masto- cytosis. Leuk Res. 2001;25(7):529-536.
86. Orazi A, Chiu R, O'Malley DP, et al. Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology. Mod Pathol. 2006;19(12):1536-1545.
87. Tuzuner N, Bennett JM. Reference standards for bone marrow cellularity. Leuk Res. 1994;18(8):645-647.
88. Tuzuner N, Cox C, Rowe JM, Bennett JM. Bone marrow cellularity in myeloid stem cell disorders: impact of age correction. Leuk Res. 1994;18(8):559-564.
89. Schemenau J, Baldus S, Anlauf M, et al. Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplas- tic syndromes. Eur J Haematol 2015;95 (3):181-189.
90. Petrova-Drus K, Chiu A, Margolskee E, et al. Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression. Oncotarget. 2017;8(61):103274-103282.
91. Khan M, Muzzafar T, Kantarjian H, et al. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol. 2018;97(7):1183-1191.
92. Horny HP, Sotlar K, Valent P. Diagnostic
value of histology and immunohistochem- istry in myelodysplastic syndromes. Leuk Res. 2007;31(12):1609-1616.
93. Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clon- al haematological non-mast cell lineage dis- eases: a histopathological challenge. J Clin Pathol. 2004;57(6):604-608.
94. Fugazza G, Bruzzone R, Dejana AM, et al. Cytogenetic clonality in chronic myelomonocytic leukemia studied with flu- orescence in situ hybridization. Leukemia. 1995;9(1):109-114.
95. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with sub- types: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-4395.
96. Wassie EA, Itzykson R, Lasho TL, et al. Molecular and prognostic correlates of cyto- genetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic- French Consortium Study. Am J Hematol. 2014;89(12):1111-1115.
97. Palomo L, Xicoy B, Garcia O, et al. Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases. Am J Hematol. 2016;91(2):185-192.
98. Steidl C, Steffens R, Gassmann W, et al. Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients. Leuk Res. 2005;29(9):987-993.
99. ISCN: an International System for Human Cytogenetic Nomenclature (2016). Eds. McGowan-Jordan J, Simons A, Schmid M. Karger Basel, New York, 2016.
100. Such E, Cervera J, Costa D, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96(3):375-383.
101. Nomdedeu M, Calvo X, Pereira A, et al.; Spanish Group of Myelodysplastic Syndromes. Prognostic impact of chromoso- mal translocations in myelodysplastic syn- dromes and chronic myelomonocytic leukemia patients. A study by the Spanish Group of Myelodysplastic Syndromes. Genes Chromosomes Cancer. 2016;55(4): 322-327.
102. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, et al. RAS mutations are rare events in Philadelphia chromosome-nega- tive/bcr gene rearrangement-negative chron- ic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood. 1990;76(6):1214-1219.
103. Kohlmann A, Grossmann V, Haferlach T. Integration of next-generation sequencing into clinical practice: are we there yet? Semin Oncol. 2012;39(1):26-36.
104. Smith AE, Mohamedali AM, Kulasekararaj A, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prog- nostic value. Blood. 2010;116(19):3923-3932.
105. Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and manage- ment. Am J Hematol. 2018;93(6):824-840.
106. Jankowska AM, Makishima H, Tiu RV, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011;118(14): 3932-3941.
107. Itzykson R, Kosmider O, Renneville A, et al. Clonal architecture of chronic myelomono- cytic leukemias. Blood. 2013;121(12):2186- 2198.
108.Patel BJ, Przychodzen B, Thota S, et al. Genomic determinants of chronic myelomonocytic leukemia. Leukemia. 2017; 31(12):2815-2823.
109. Gelsi-Boyer V, Trouplin V, Roquain J, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010;151(4):365-375.
110.Federmann B, Abele M, Rosero Cuesta DS, et al. The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia. Hum Pathol. 2014;45(12):2471-2479.
111. Bally C, Adès L, Renneville A, et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leuk Res. 2014;38(7):751-755.
112.Padua RA, Guinn BA, Al-Sabah AI, et al. RAS, FMS and p53 mutations and poor clin- ical outcome in myelodysplasias: a 10-year follow-up. Leukemia. 1998;12(6):887-892.
113. Ricci C, Fermo E, Corti S, et al. RAS muta- tions contribute to evolution of chronic myelomonocytic leukemia to the prolifera- tive variant. Clin Cancer Res. 2010;16 (8):2246-2256.
114. Wang J, Liu Y, Li Z, et al. Endogenous onco- genic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocyt- ic precursors in a murine model of chronic myelomonocytic leukemia. Blood. 2010;116 (26):5991-6002.
115. Padron E, Painter JS, Kunigal S, et al. GM- CSF-dependent pSTAT5 sensitivity is a fea- ture with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013;121 (25):5068-5077.
116.Geissler K, Jäger E, Barna A, et al. Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors. Leukemia. 2016;30(11):2280-2281.
117. Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428-2436.
118. Elena C, Gallì A, Such E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128 (10):1408-1417.
119.Palomo L, Garcia O, Arnan M, et al. Targeted deep sequencing improves out- come stratification in chronic myelomono- cytic leukemia with low risk cytogenetic features. Oncotarget. 2016;7(35):57021- 57035.
120.Onida F. Models of Prognostication in chronic myelomonocytic leukemia. Curr Hematol Malig Rep. 2017;12(6):513-521.
121. Xu Y, McKenna RW, Karandikar NJ, Pildain AJ, Kroft SH. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol. 2005;124(5):799-806.
122.Lacronique-Gazaille C, Chaury MP, Le Guyader A, Faucher JL, Bordessoule D, Feuillard J. A simple method for detection of major phenotypic abnormalities in myelodysplastic syndromes: expression of CD56 in CMML. Haematologica. 2007;92 (6):859-860.
123. Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T. Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotyp- ic features but differ in the extent of aber-
1948
haematologica | 2019; 104(10)